Publicaciones en colaboración con investigadores/as de Universidad de Oviedo (23)

2020

  1. Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates

    Brain Structure and Function, Vol. 225, Núm. 7, pp. 2153-2164

  2. Expression of cannabinoid CB1R–GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum

    Annals of the New York Academy of Sciences, Vol. 1475, Núm. 1, pp. 34-42

2019

  1. Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease

    Molecular Neurobiology, Vol. 56, Núm. 8, pp. 5900-5910

  2. The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042

    Journal of Clinical Medicine, Vol. 8, Núm. 8

2018

  1. Cancertool: A visualization and representation interface to exploit cancer datasets

    Cancer Research, Vol. 78, Núm. 21, pp. 6320-6328

  2. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 6, Núm. 10, pp. 771-781

2017

  1. Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors

    Frontiers in Pharmacology, Vol. 8, Núm. OCT

2016

  1. Basic pharmacological and structural evidence for class A G-protein-coupled receptor heteromerization

    Frontiers in Pharmacology, Vol. 7, Núm. MAR

  2. Two affinity sites of the cannabinoid subtype 2 receptor identified by a novel homogeneous binding assay

    Journal of Pharmacology and Experimental Therapeutics, Vol. 358, Núm. 3, pp. 580-587

2015

  1. A labor and cost effective next generation sequencing of PKHD1 in autosomal recessive polycystic kidney disease patients

    Gene, Vol. 561, Núm. 1, pp. 165-169

  2. The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients

    Journal of Human Genetics, Vol. 60, Núm. 5, pp. 273-276

2014

  1. A labor- and cost-effective non-optical semiconductor (Ion Torrent) next-generation sequencing of the SLC12A3 and CLCNKA/B genes in Gitelman's syndrome patients

    Journal of Human Genetics, Vol. 59, Núm. 7, pp. 376-380

  2. Effect of the FTO rs9930506 Polymorphism on the Main Comorbidities of the Cardiorenal Metabolic Syndrome in an Elderly Spanish Cohort

    CardioRenal Medicine, Vol. 4, Núm. 2, pp. 82-87

  3. Mitochondrial DNA haplogroups and risk of new-onset diabetes among tacrolimus-treated renal transplanted patients

    Gene, Vol. 538, Núm. 1, pp. 195-198

2013

  1. A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort

    Gene, Vol. 527, Núm. 2, pp. 670-672

  2. A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients

    Pharmacogenetics and Genomics, Vol. 23, Núm. 8, pp. 445-448

2012

  1. Resequencing the whole MYH7 gene (including the intronic, promoter, and 3′ UTR sequences) in hypertrophic cardiomyopathy

    Journal of Molecular Diagnostics, Vol. 14, Núm. 5, pp. 518-524

2011

  1. El complejo escenario de las alteraciones de metabolismo óseo y mineral en la enfermedad renal crónica

    Nefrologia, Vol. 31, Núm. 5, pp. 514-519

  2. Erratum: Pharmacogenetics of tacrolimus after renal transplantation: Analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes (Clinical Chemistry and Laboratory Medicine (2011) 49:5 (825-833))

    Clinical Chemistry and Laboratory Medicine

  3. Pharmacogenetics of tacrolimus after renal transplantation: Analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes

    Clinical Chemistry and Laboratory Medicine, Vol. 49, Núm. 5, pp. 825-833